Role of mast cells and lipid mediators for postischemic leukocyte responses.

Abstract

<p>Cremasteric ruthenium-red-positive mast cells (A; arrows). The number of ruthenium red-positive cells in mice treated with TXA, EACA, aprotinin, cromolyn, MK-886, or BN52021 undergoing I/R (B). Leukocyte firm adherence (C) and transmigration (D) in mast cell-depleted mice as well as in mice treated with cromolyn, BN52021, or MK-886 undergoing I/R (mean±SEM for <i>n</i> = 4–5 per group; #p<0.05, vs. sham; *p<0.05, vs. vehicle).</p